Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis.

Antimicrobial Agents and Chemotherapy
Srinivas V RamaswamyEdward A Graviss

Abstract

Isoniazid (INH) is a central component of drug regimens used worldwide to treat tuberculosis. Previous studies have identified resistance-associated mutations in katG, inhA, kasA, ndh, and the oxyR-ahpC intergenic region. DNA microarray-based experiments have shown that INH induces several genes in Mycobacterium tuberculosis that encode proteins physiologically relevant to the drug's mode of action. To gain further insight into the molecular genetic basis of INH resistance, 20 genes implicated in INH resistance were sequenced for INH resistance-associated mutations. Thirty-eight INH-monoresistant clinical isolates and 86 INH-susceptible isolates of M. tuberculosis were obtained from the Texas Department of Health and the Houston Tuberculosis Initiative. Epidemiologic independence was established for all isolates by IS6110 restriction fragment length polymorphism analysis. Susceptible isolates were matched with resistant isolates by molecular genetic group and IS6110 profiles. Spoligotyping was done with isolates with five or fewer IS6110 copies. A major genetic group was established on the basis of the polymorphisms in katG codon 463 and gyrA codon 95. MICs were determined by the E-test. Semiquantitative catalase assays were pe...Continue Reading

References

Mar 1, 1996·Molecular Microbiology·T M Wilson, D M Collins
Jan 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D L CohnM C Raviglione
Sep 2, 1997·Proceedings of the National Academy of Sciences of the United States of America·S SreevatsanJ M Musser
Sep 18, 1997·JAMA : the Journal of the American Medical Association·M MooreK G Castro
Sep 26, 1997·Antimicrobial Agents and Chemotherapy·C L KelleyS L Morris
Oct 23, 1998·Microbiology·Fabienne BardouGilbert Lanŕelle
Oct 27, 1999·Proceedings of the National Academy of Sciences of the United States of America·M WilsonG K Schoolnik
Jan 25, 2000·Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease·S Ramaswamy, J M Musser
Oct 4, 2000·Journal of Clinical Microbiology·M L JolobaM R Jacobs
Mar 17, 2001·Molecular Microbiology·T C ZahrtV Deretic
Jun 16, 2001·Antimicrobial Agents and Chemotherapy·A S LeeS Y Wong
Jul 17, 2001·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G AbateH Miörner

❮ Previous
Next ❯

Citations

Jan 16, 2008·Accounts of Chemical Research·Hao Lu, Peter J Tonge
Aug 15, 2006·Nature Medicine·Catherine VilchèzeWilliam R Jacobs
Jul 19, 2012·Journal of Biomolecular Structure & Dynamics·Jyothi PadiadpuNagasuma Chandra
May 25, 2005·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Pere CollMargarita Salvadó
Jan 18, 2007·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Xin JiangHonghai Wang
Mar 7, 2008·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Xin JiangHonghai Wang
Dec 19, 2008·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Farahnoosh DoustdarAli Akbar Velayati
Jul 7, 2009·The Journal of Antimicrobial Chemotherapy·Indra L BergvalRichard M Anthony
May 12, 2011·The Journal of Antimicrobial Chemotherapy·Pedro Eduardo Almeida Almeida Da Silva, Juan Carlos Palomino
Feb 1, 2012·The Journal of Antimicrobial Chemotherapy·Rachid NessarBrigitte Gicquel
Jul 28, 2006·Antimicrobial Agents and Chemotherapy·Manzour Hernando HazbónDavid Alland
Jul 2, 2008·Antimicrobial Agents and Chemotherapy·Manzour Hernando HazbónDavid Alland
May 20, 2009·Antimicrobial Agents and Chemotherapy·G E LouwT C Victor
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Stéphanie Ducasse-CabanotAnnaïk Quémard
Sep 29, 2005·Antimicrobial Agents and Chemotherapy·Caroline LavenderJanet Fyfe
Jan 28, 2005·Antimicrobial Agents and Chemotherapy·Catherine VilchèzeWilliam R Jacobs
Nov 17, 2006·Journal of Clinical Microbiology·Jun-ichiro SekiguchiTeruo Kirikae
Dec 14, 2007·Journal of Clinical Microbiology·I L BergvalR M Anthony
Sep 14, 2012·Journal of Clinical Microbiology·Luke T DaumGerald W Fischer
Mar 9, 2004·Journal of Clinical Microbiology·Manzour Hernando Hazbón, David Alland
Nov 24, 2007·Annual Review of Microbiology·Catherine Vilchèze, William R Jacobs

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.